30
Participants
Start Date
October 10, 2024
Primary Completion Date
July 28, 2025
Study Completion Date
September 22, 2025
RAP-219
RAP-219 oral tablet
NYU Langone Comprehensive Epilepsy Center, New York
University of Pennsylvania - Department of Neurology, Philadelphia
Thomas Jefferson University, Philadelphia
Vanderbilt University Medical Center, Nashville
Cleveland Clinic Foundation, Cleveland
IU Health Neuroscience Center, Goodman Hall, Indianapolis
Mayo Clinic, Rochester
The University of Kansas Medical Center Epilepsy Clinic, Kansas City
University of Texas Health Science Center, Houston, Houston
Consultants in Epilepsy and Neurology, PLLC, Boise
Baylor College of Medicine, Houston
Yale University, New Haven
Rapport Therapeutics Inc.
INDUSTRY